Mechanism
CJC-1295 Ipamorelin as a Growth Hormone Secretagogue
What the term means, which arm each peptide occupies, and why ipamorelin earned the word 'selective.'
In plain English
A growth hormone secretagogue is anything that makes the body release more of its own growth hormone, rather than supplying growth hormone from outside. The CJC-1295 Ipamorelin pairing is a secretagogue approach in this exact sense: it does not add growth hormone, it coaxes the pituitary gland to make more. It does this through two different controls. CJC-1295 works the GHRH control — the natural "make growth hormone" signal — and is built to keep working for days. Ipamorelin works a second control, the ghrelin receptor, the same switch the hunger hormone uses, and it does so unusually cleanly: it releases growth hormone without setting off the stress hormones that older peptides in its class disturbed. This page explains what each arm does, why the combination is described as supra-additive (greater than the sum of its parts), and what the class-wide safety picture looks like. As elsewhere on this site, the blend itself has no trial — the evidence is single-component and general.
What the term means
In endocrinology, a secretagogue is an agent that triggers secretion. A growth hormone secretagogue triggers the pituitary's own GH release. The category divides by mechanism: GHRH analogues act on the GHRH receptor (a class-B GPCR that raises cAMP), while GHRPs — growth-hormone-releasing peptides — act on the ghrelin receptor, GHS-R1a (which raises intracellular calcium). CJC-1295 is the GHRH-analogue type; ipamorelin is the GHRP type. Because the two receptors sit on the same somatotroph cell yet signal through independent pathways, an agent from each category can be combined for a larger effect than either produces alone [3] [4].
The two arms in detail
The GHRH arm — CJC-1295 — binds the GHRH receptor and drives GH synthesis and release; its DAC form binds albumin for a multi-day half-life, sustaining GH and IGF-1 elevation for days after a single dose in humans [1] [5]. The ghrelin arm — ipamorelin — binds GHS-R1a, raises calcium, and triggers a quick GH pulse, while also partly working by opposing somatostatin, the brake the body uses to limit GH. Ipamorelin's signature is its cleanliness: it is the first selective GH secretagogue, releasing GH without raising ACTH or cortisol above GHRH-stimulated levels even at very high multiples of its effective dose, while matching GHRP-6's GH efficacy in swine [2]. That selectivity is why it is preferred over the older, messier GHRPs in the combination.
Why combine two secretagogues
Combining a GHRH analogue with a GHRP is the oldest validated idea in this space. In normal men, submaximal GHRP doses combined with GHRH stimulated GH release synergistically, the two acting through independent mechanisms [3]; co-activating the two receptors in transfected cells roughly doubled the cAMP signal of GHRH alone [4]. The practical rationale for the CJC-1295 ipamorelin pairing follows directly: a long-acting GHRH background (CJC-1295) keeps the GHRH receptor engaged, while the selective ghrelin-receptor pulse (ipamorelin) adds a clean burst on top — together producing a larger, more physiological-looking GH release than either arm alone. The rationale is well grounded; the specific blend's pulse profile is not characterized in any controlled study.
The class safety signal
As a class, growth hormone secretagogues carry a consistent and well-described safety signal. A review of the class found the compounds generally well tolerated, with the chief concern being increased blood glucose from decreased insulin sensitivity, and with long-term data on cancer incidence and mortality still needed [6]. Because raising GH also raises IGF-1 — a mitogen — the theoretical oncologic caution applies to any secretagogue strategy, including this one [1]. These are the same cautions detailed, with their mechanisms, on the CJC-1295 Ipamorelin effects page; they belong to the secretagogue category as a whole, not uniquely to one product.